An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care With and Without Oral Corticosteroids in Patients With Active Lupus Nephritis Class III-IV, +/- V

  • End date
    Mar 13, 2028
  • participants needed
  • sponsor
    Novartis Pharmaceuticals
Updated on 21 October 2022
treatment regimen
antimalarial agents


The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.


The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.

Condition Lupus Nephritis
Treatment Iptacopan (part 1), Iptacopan (part 2), Placebo + standard of care, Iptacopan + placebo
Clinical Study IdentifierNCT05268289
SponsorNovartis Pharmaceuticals
Last Modified on21 October 2022


Yes No Not Sure

Inclusion Criteria

Unequivocally positive ANA test result and/or a positive anti dsDNA at screening Active
biopsy-proven lupus nephritis within 3 months of screening demonstrating Class III or IV
lupus nephritis with or without co-existing features of Class V lupus nephritis
Documentation of active renal disease at the time of screening necessitating the
commencement of therapy with corticosteroids in combination with MMF/MPS
eGFR ≥ 30 ml/min/1.73 m2 Vaccination against Neisseria meningitidis and Streptococcus
pneumoniae infections Vaccination against Haemophilus influenzae infection Supportive care
including stable dose regimen of anti-malarials (e.g. hydroxychloroquine) unless
contraindicated, ACEi or ARB at either locally approved maximal daily dose or the maximally
tolerated dose (per investigators' judgement) at screening, as per the local clinical
practice. Doses should remain stable throughout the study
First presentation or flare of lupus nephritis

Exclusion Criteria

Induction treatment with cyclophosphamide within 3 months of planned treatment for this
study; treatment with calcineurin inhibitors within the previous 3 months prior to
screening Presence of rapidly progressive glomerulonephritis (RPGN) as defined by 50%
decline in eGFR within 3 months prior to screening
Renal biopsy presenting with interstitial fibrosis/tubular atrophy (IF/TA) or
glomerulosclerosis of more than 50%, or which in the opinion of the investigator is such
that it precludes likely response to immunosuppressive therapy
Participants being treated with systemic corticosteroids (>5 mg/day prednisone or
equivalent) for indications other than SLE or LN e.g. acute asthma, inflammatory bowel
Participants being treated with systemic corticosteroids for SLE or LN will be excluded if
they have taken more than an average of 10 mg/day prednisone (or equivalent) in the
previous 4 weeks and more than an average of 20 mg/day in the previous 1 week Receipt of
more than a total dose of 1000 mg equivalent i.v. pulse methylprednisolone (cumulative
dose) within 2 weeks prior to enrollment (and at enrollment)
Other protocol-defined inclusion/exclusion criteria may apply
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note